[1] 赵泽华,刘晓琳,范建高.重视非酒精性脂肪性肝病自然史的研究.中华肝脏病杂志,2017,25:81-84.
[2] Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol,2017, 67:1265-1273.
[3] Ratziu V. Back to Byzance: Querelles byzantines over NASH and fibrosis. J Hepatol,2017,67: 1134-1136.
[4] Diehl AM, Day C. Cause,pathogenesis,and treatment of nonalcoholic steatohepatitis. N Engl J Med, 2017, 377:2063-2073.
[5] Goldberg D, Ditah IC, Saeian K, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology, 2017,152:1090-1099.
[6] Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology,2015,61:1547-1554.
[7] Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 2015,149:389-397.
[8] Sanyal AJ, Friedman SL, McCullough AJ, et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology, 2015,61:1392-1405.
[9] EASL. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol,2016,64:1388-1402.
[10] Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol,2015,13:643-654.
[11] Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: Current and Emerging. J Hepatol,2018,68:362-375. |
